Prognostic value of lipoprotein fractions in essential hypertension

References

• Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837–47.
   PubMed Web of Science ®Google Scholar
• Anonymous. National Education Programs Working Group report on the management of patients with hypertension and high blood cholesterol. Ann Intern Med 1991; 114: 224–37.
   PubMedGoogle Scholar
• Meigs JB, D'Agostino RB Sr, Wilson PW, Cupples LA, Nathan DM, Singer DE. Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study. Diabetes 1997; 46: 1594–600.
   Google Scholar
• Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure, and mortality: impli-cations from a cohort of 361,662 men. Lancet 1986; 2: 933–36.
   Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–7.
   PubMed Web of Science ®Google Scholar
• Guidelines Committee. 2003 European Society of Hyper-tension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–53.
   Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the INC 7 report. JAMA 2003; 289: 2560–72.
   Google Scholar
• Alderman MH, Cohen H, Madhavan S. Distribution and determinants of cardiovascular events during 20 years of successful antihypertensive treatment. J Hypertens 1998; 16: 761–9.
   Google Scholar
• Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366–72.
   PubMed Web of Science ®Google Scholar
• Zanchetti A, Hansson L, Dahlof B, et al. Effects of indi-vidual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. J Hypertens 2001; 19: 1149–59.
   PubMed Web of Science ®Google Scholar
• Gueyffier F, Boissel JP, Pocock S, et al. Identification of risk factors in hypertensive patients: contribution of randomized controlled trials through an individual patient database. Circulation 1999; 100: e88–94.
   PubMedGoogle Scholar
• Verdecchia P, Porcellati C, Schillaci G, et al. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension 1994; 24: 793–801.
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97: 48–54.
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic validation of a new electrocardiographic method for diag-nosis of left ventricular hypertrophy in essential hyper-tension. J Am Coll Cardiol 1998; 31: 383–90.
   PubMed Web of Science ®Google Scholar
• Schillaci G, Verdecchia P, Borgioni C, et al. Improved electrocardiographic diagnosis of left ventricular hypertro-phy. Am J Cardiol 1994; 74: 714–19.
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Schillaci G, Boldrini F, Guerrieri M, Zampi I, Porcellati C. Quantitative assessment of day-to-day sponta-neous variability in non-invasive ambulatory blood pressure measurements in essential hypertension. J Hypertens 1991; 9 Suppl 6: S322–3.
   Google Scholar
• Cox DR. Regression models and life-tables. J R Stat Soc B 1972; 34: 187–220.
   Google Scholar
• The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97.
   Google Scholar
• Wilson PW, Anderson KM, CasteIli WP. Twelve-year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy: the Framingham offspring study. Am J Med 1991; 90: 11–16.
   Google Scholar
• Prospective Studies Collaboration. Cholesterol, diastolic blood pressure and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts. Lancet 1995; 346: 1647–53.
   PubMed Web of Science ®Google Scholar
• Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol, and stroke in eastern Asia. Lancet 1998; 352: 1801–7.
   Google Scholar
• Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989; 320: 904–10.
   PubMed Web of Science ®Google Scholar
• Sacco RL, Benson RT, Kargman DE, et al. High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA 2001; 285: 2729–35.
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Schillaci G, Reboldi G, Franklin SS, Porcellati C. Different prognostic impact of 24-hour mean blood pressure and pulse pressure on stroke and coronary artery disease in essential hypertension. Circulation 2001; 103: 2579–84.
   Google Scholar
• Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 1997; 96: 2520–5.
   Google Scholar
• Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996; 276: 882–8.
   PubMed Web of Science ®Google Scholar
• LaRosa JC. Triglycerides and coronary risk in women and the elderly. Arch Intern Med 1997; 157: 961–8.
   PubMed Web of Science ®Google Scholar
• Hokanson JE, Autsin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213–9.
   PubMedGoogle Scholar
• Brenner H, Heiss G. The intraindividual variability of fasting triglyceridea challenge for further standardization.Eur Heart J 1990; 11: 1054–8.
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlöf B, Poulter NR, et al. for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes TrialLipidLowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–58.
   Google Scholar